Press Releases and Events

PRESS RELEASES

Press Release | October 23, 2025

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

READ MORE
Press Release | October 10, 2025

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | October 6, 2025

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

READ MORE
Press Release | September 25, 2025

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults

READ MORE
Press Release | September 10, 2025

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | August 21, 2025

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

READ MORE
Press Release | August 11, 2025

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
Press Release | August 7, 2025

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

READ MORE
Press Release | July 13, 2025

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

READ MORE
Press Release | July 11, 2025

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

READ MORE
3 / 24